Mirdametinib  (Synonyms: PD0325901; PD325901)

Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor^[1][2][3].

Mirdametinib (250 nM; 7 d) induces differentiation of cardiac PCs into vascular smooth muscle cell (VSMC)-like cells^[1].
Mirdametinib (10 μM; 4 d) induces oligodendrocyte precursor cells (OPC) to oligodendrocytes (OL) differentiation^[2].
Mirdametinib enhances embryonic stem cells (ESC) self-renewal capacity both by key regulatory genes and ES cell-specific miRNA, which in turn influences ESC self-renewal and cellular differentiation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

482.19

C₁₆H₁₄F₃IN₂O₄

391210-10-9

O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Avolio E, et al. Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. J Clin Invest. 2022 May 16;132(10):e152308.  [Content Brief]

  [2]. Suo N, et al. Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases. Glia. 2019 Jul;67(7):1320-1332.  [Content Brief]

  [3]. Ai Z, et al. Maintenance of Self-Renewal and Pluripotency in J1 Mouse Embryonic Stem Cells through Regulating Transcription Factor and MicroRNA Expression Induced by PD0325901. Stem Cells Int. 2016;2016:1792573.  [Content Brief]